Best Peptides for Weight Loss 2026: What Actually Works

Here's where things stand in 2026: the peptide-for-weight-loss space has been completely reshaped by two compounds: semaglutide and tirzepatide. If you've spent any time on health forums lately, you already know this. But there's a lot of noise around what else works, what's overhyped, and how these compounds are actually being used. We're going to cut through it. This isn't a list of everything that theoretically might affect body composition. It's a ranked breakdown of the peptides with the strongest evidence base, how they differ from each other, and what the research-based community is actually running. As always, talk to your doctor before starting anything new. These compounds have real physiological effects and real risks.

Tirzepatide is the current gold standard in the peptide space for weight loss. Period. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed average weight reduction of 20.9% at the highest dose (15 mg weekly) over 72 weeks. That's approaching bariatric surgery territory. And it outperformed semaglutide in head-to-head comparison in the SURMOUNT-5 trial (2024), where tirzepatide users lost an average of 20% vs. 13.7% with semaglutide. The mechanism explains why: tirzepatide activates both GLP-1 and GIP receptors simultaneously. GLP-1 slows gastric emptying and reduces appetite. GIP appears to enhance the GLP-1 effect and may have independent effects on adipose tissue. Dual action = greater effect. What most guides won't tell you: tirzepatide also shows significantly better glycemic control than semaglutide, which is why it was initially approved for T2D before weight loss. If metabolic health is a consideration alongside fat loss, tirzepatide has an additional argument in its favor. Sourcing note: Tirzepatide is prescription-only as Mounjaro/Zepbound. Research peptide vendors sell it as a research compound: verify COA and source carefully.

Semaglutide was the big story of 2022-2024, and the evidence is genuinely impressive. The STEP-1 trial (Wilding et al., NEJM, 2021): 1,961 adults, 68 weeks: showed average weight loss of 14.9% with 2.4 mg weekly semaglutide vs. 2.4% placebo. That's a 12.5 percentage point drug-attributable effect in a well-designed RCT. This is the foundation of the GLP-1 weight loss story. Semaglutide works primarily through GLP-1 receptor agonism: slowing gastric emptying, reducing appetite signaling, and improving insulin sensitivity. The appetite suppression effect is real and consistent across most users. The practical difference between sema and tirze: semaglutide tends to have a somewhat more gradual effect on appetite and is generally considered to have a slightly better GI tolerance profile in the early weeks, though tirzepatide's greater efficacy means it's increasingly the first-line choice.

AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of the C-terminal region of human growth hormone: specifically the amino acids 176-191. The idea is to isolate the fat-metabolizing properties of GH without the anabolic or diabetogenic effects. The early animal research was genuinely promising. Ng et al. (2000) showed significant fat reduction in obese mice. The problem: human trials haven't replicated the dramatic effects seen in animal models. Phase II trials in the early 2000s showed modest results in humans, which led to the drug not progressing to Phase III. Where AOD-9604 fits in 2026: It's a compound worth knowing about, especially for users who want GH-adjacent fat metabolism effects without the full GH side effect profile. But the evidence base is substantially weaker than GLP-1 agonists or even the GH secretagogue stack.

TB-500 and BPC-157 are in the fat loss conversation primarily because they allow people to train harder and recover faster. The logic: if you're not limited by injury or recovery, you can maintain training volume. More training volume supports fat loss. That's a real and valid use case, but it's very different from direct fat metabolism. If you're looking at these compounds primarily for weight loss rather than injury recovery and training support, you're looking at the wrong tools.

Based on what we see in the research community and r/Peptides discussions, the most common fat loss protocols in 2026 are: Protocol A -- Maximum fat loss: Tirzepatide 5-15 mg weekly (titrated up over 8-12 weeks), high-protein diet, resistance training Protocol B -- Recomp focus: CJC-1295 + Ipamorelin (100-200 mcg each, 2-3x daily) + caloric deficit + resistance training Protocol C -- Combined approach: Low-dose semaglutide (0.5-1 mg weekly) + CJC-1295/Ipamorelin stack. Some users report this combination provides both appetite control and improved body composition vs. either alone. There's limited formal research on Protocol C specifically, but the mechanism makes sense physiologically. Both the GLP-1 and GH axes affect body composition through different pathways that don't directly compete.

Based on clinical trial data, tirzepatide produces the greatest average weight reduction: 20%+ of body weight in SURMOUNT-1. Semaglutide averages around 15%. GH secretagogue stacks like CJC-1295 + Ipamorelin produce smaller and more variable results, primarily in the body recomposition range rather than pure weight reduction.

The clinical trials showing 15-20% weight loss with semaglutide and tirzepatide were conducted alongside dietary counseling and lifestyle modification. That said, the appetite suppression effect of GLP-1 agonists is strong enough that many users naturally reduce caloric intake. Significant weight loss from peptides without any dietary change is unlikely; meaningful weight loss with modest dietary changes is well-documented.

GLP-1 agonists typically show appetite suppression effects within the first 2-4 weeks, with meaningful weight loss visible at 8-12 weeks. The peak effect in clinical trials wasn't reached until 40-70 weeks. GH secretagogue stacks show slower body composition changes: most community reports describe noticing recomp effects after 8-12 weeks.

GLP-1 agonists are used continuously in clinical settings. GH secretagogues are typically cycled (8-12 weeks on, 4 weeks off) based on community consensus and receptor sensitivity concerns.

1. Jastreboff et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 2022. 2. Wilding et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021. 3. SURMOUNT-5 trial results: tirzepatide vs. semaglutide head-to-head comparison (2024) 4. Ng et al. "The amino-terminal fragment of human growth hormone with anti-obesity effects." Endocrinology, 2000. 5. Sikiric et al. "Stable Gastric Pentadecapeptide BPC 157." Current Pharmaceutical Design, 2018. 6. FDA Black Box Warning: GLP-1 receptor agonists and thyroid C-cell tumor risk (2022 update) 7. r/Peptides community survey data: body composition protocols (2025-2026)